Antiviral Discovery for Highly Pathogenic Emerging Viruses

The need for new antiviral drugs is highlighted by recent outbreaks, such as Zika and Ebola. Antiviral Discovery for Highly Pathogenic Emerging Viruses provides an overview of the state of the art in antiviral drug discovery, including targets, screening strategies, and the pipeline of candidates. It also addresses the challenges faced in developing these agents for clinical trials.

Format: Hardback
Length: 290 pages
Publication date: 08 December 2021
Publisher: Royal Society of Chemistry

The urgent need for new antiviral drugs is underscored by recent outbreaks caused by viruses with significant epidemiological impact, such as Zika, Ebola, Nipah, Lassa, and Crimean-Congo hemorrhagic fever. These outbreaks highlight the lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses provides a comprehensive overview of the state-of-the-art in antiviral drug discovery, encompassing target identification, screening strategies, and the current pipeline of antiviral candidates. The book also addresses the challenges faced in transitioning from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents.

Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book offers a comprehensive overview of the latest progress in the field, recent advances, and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies, this book serves as a valuable resource in this complex and multidisciplinary field.

Weight: 610g
Dimension: 163 x 240 x 26 (mm)
ISBN-13: 9781788015646